TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd. (NASDAQ:ROIV) on February 6, revising the price target on the stock to $38 from $28 and maintaining a Buy rating. The rating update came the same day Roivant Sciences Ltd. (NASDAQ:ROIV) announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for Q3 ended December 31, 2025.

Roivant Sciences Ltd. (NASDAQ:ROIV) reported that brepocitinib 45 mg considerably improved cutaneous sarcoidosis disease activity and exhibited rapid, deep, and sustained improvements across all other efficacy endpoints measured with a consistent safety profile. Management further stated that an NDA was submitted to the FDA for brepocitinib in dermatomyositis (DM), with topline data from Phase 3 studies in non-infectious uveitis (NIU) anticipated in H2 of calendar year 2026. Roivant Sciences Ltd. (NASDAQ:ROIV) is continually exploring other indications for brepocitinib.

In addition, the company reported $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025, supporting cash runway into profitability.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company that develops transformative medicines. Its product portfolio comprises Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. Its product candidates extend across various therapeutic areas, including oncology, immunology, dermatology, and hematology.

While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.